A total of 880 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of United States, in the last twelve months resulting in a total deal value of over $44,058.3 million. In the LTM period, July 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $11,203.4 million, resulting in an average deal value of $164.8 million during that month. On the other hand, the month of December 2021 was the most prolific in terms of deal volume, recording a total of 89 deals, resulting in an average deal value of $20.2 million during that month.
Of the 880 deals, the deal secured between EQT AB; EQT Partners AB; Goldman Sachs Asset Management LP and Parexel International Corp, was the largest Private Equity/Venture Financing deal in the United States Pharmaceuticals sector, which was valued at $8,500.0 million and was completed on July 2, 2021. The second-largest deal was between Patient Square Capital LP and Summit Behavioral Healthcare LLC, while the third-largest deal was between Andreessen Horowitz LLC; Avidity Partners LLC; Bain Capital Life Sciences; Boxer Capital LLC; BVF Partners LP; Fidelity Management & Research Company; Franklin Templeton Investments Corp; Invus LP; Mubadala Capital; Mubadala Investment Co; Rock Springs Capital Management LP; SB Northstar LP; Verily Life Sciences and EQRx Inc. The Patient Square Capital LP-Summit Behavioral Healthcare LLC deal and the Andreessen Horowitz LLC; Avidity Partners LLC; Bain Capital Life Sciences; Boxer Capital LLC; BVF Partners LP; Fidelity Management & Research Company; Franklin Templeton Investments Corp; Invus LP; Mubadala Capital; Mubadala Investment Co; Rock Springs Capital Management LP; SB Northstar LP; Verily Life Sciences-EQRx Inc deal were valued at $1,300.0 million and $1,200.0 million, respectively. The fourth-largest deal was between Gurnet Point Capital Ltd; Patient Square Capital LP-Radius Health Inc valued at $890.0 million, whereas the deal between aMoon Partners; Andreessen Horowitz LLC; D1 Capital Partners; Founders Fund; General Atlantic LLC; Khosla Ventures LLC; Lightspeed Management Company, L.L.C; Marius Nacht; Playground Global LLC-Ultima Genomics Inc valued at $600.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $12,490.0 million and accounted for nearly 28.35% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer